A leaked report reveals that British cancer patients are being denied access to life-saving drugs and innovative treatments due to increased costs and regulatory hurdles caused by Brexit. The analysis, conducted by experts including Cancer Research UK and the University of Southampton, found that clinical trial costs have surged, with some drug import and shipping expenses quadrupling. These challenges have hindered the UK’s ability to participate in international clinical trials, limit collaboration with EU researchers, and discourage global cancer research talent from coming to the UK. The report cites severe impacts on NHS patients, including children whose treatments have failed or been halted. Duplication of drug testing and additional bureaucracy have caused significant delays, affecting research productivity and patient care. Experts say these negative consequences were foreseeable outcomes of a hard Brexit. The government claims it is working to strengthen research ties with the EU and support UK researchers through initiatives like the Horizon Europe program. The report urges the creation of a mutual recognition agreement for medicines testing to prevent future delays and mitigate the effects on patient treatment and research progress.
NHS Cancer Patients Denied Life-Saving Drugs Due to Brexit Costs
